| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Asundexian | BAY-2433334 | Phase 3 Clinical | Bayer AG | Atrial Fibrillation; Embolism; Hepatic Insufficiency; Ischemic Attack, Transient; Ischemic Stroke; Myocardial Infarction; Stroke; Thromboembolism | Details |
| Cenvacibart | REGN7508 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Atrial Fibrillation; Peripheral Arterial Disease; Thrombosis; Venous Thromboembolism | Details |
| Milvexian | BMS-986177; JNJ-70033093; JNJ-3093 | Phase 3 Clinical | Bristol-Myers Squibb Company | Acute Coronary Syndrome; Atrial Fibrillation; Contraception; Coronary Thrombosis; Embolism; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Renal Insufficiency; Stroke; Thromboembolism; Thrombosis | Details |
| SHR-2004 | SHR-2004 | Phase 3 Clinical | Beijing Suncadia Medicine Co Ltd | Arterial Thromboembolism; Atrial Fibrillation; Dyslipidemias; Thromboembolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis | Details |
| Amrecibart | REGN-9933 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Atrial Fibrillation; Peripheral Arterial Disease; Venous Thromboembolism | Details |
| Abelacimab | MAA-868; NOV-12 | Phase 3 Clinical | Novartis Pharma Ag | Atrial Fibrillation; Embolism; Neoplasms; Pulmonary Embolism; Stroke; Thromboembolism; Venous Thromboembolism; Venous Thrombosis | Details |
| EP-7041 | EP-7041; HSK-36273 | Phase 2 Clinical | Exithera Pharmaceuticals Inc | Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Thrombocytopenia; Thromboembolism; Thrombosis | Details |
| Osocimab | BAY-1213790 | Phase 2 Clinical | Bayer AG | Kidney Diseases; Kidney Failure, Chronic; Thromboembolism | Details |
| IONIS-FXIRX | ISIS-404071; BAY-2306001; ISIS-FXIRX; FXI-ASO; IONIS-FXIRX; ISIS-416858 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Thrombosis; Venous Thromboembolism | Details |
| MK-2060 | MK-2060 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases; Kidney Failure, Chronic; Thromboembolism; Thrombosis | Details |
| SRSD-107 | SRSD-107; SRSD107 | Phase 2 Clinical | Sirius Therapeutics Inc | Arterial Thromboembolism; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Peripheral Arterial Disease; Thromboembolism; Thrombosis; Venous Thromboembolism | Details |
| RBD-4059 | RBD-4059; RBD4059; SR059; SR-059 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Coronary Artery Disease; Coronary Disease; Kidney Failure, Chronic; Venous Thrombosis | Details |
| KN-060 | KN-060; KN060 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Essential Hypertension; Hypertension; Kidney Failure, Chronic; Obesity; Overweight; Thromboembolism | Details |
| Ir-CPI | BIOX-101; Ir-CPI | Phase 2 Clinical | Free University Of Brussels | Cerebral Hemorrhage | Details |
| Fesomersen | ION-957943; IONIS-FXI-LRx; BAY-2976217 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Nephrosis; Thromboembolism | Details |
| ONO-7269 | ONO-7269 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Cerebral Infarction | Details |
| BAY-1831865 | AB-012; BAY-1831865 | Phase 1 Clinical | Aronora Inc | Thrombosis | Details |
| A-336 | A336; A-336 | Phase 1 Clinical | Klus Pharma | Thromboembolism | Details |
| A-186 | A-186 | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Thromboembolism | Details |
| BMS-262084 | BMS-262084 | Phase 1 Clinical | Bristol-Myers Squibb Company | Thrombosis | Details |
| ADX-626 | ADX-626 | Phase 1 Clinical | ADARx Pharmaceuticals Inc | Thrombosis | Details |
| SBK-013 | SBK013; SBK-013 | Phase 1 Clinical | Chengdu Shibeikang Biomedical Technology Co Ltd | Arterial Thromboembolism; Thromboembolism; Venous Thromboembolism | Details |
| XH-S002 | XH-S002; XHS002 | Phase 1 Clinical | Ischemic Attack, Transient; Stroke | Details | |
| BMS-986209 | BMS-986209 | Phase 1 Clinical | Bristol-Myers Squibb Company | Details | |
| NIP-003 | NIP003; NIP-003; CRB4101; CRB-4101 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Thromboembolism; Venous Thromboembolism; Venous Thrombosis | Details |
| Factor XIa Inhibitor (Bayer) | Factor XIa Inhibitor (Bayer) | Phase 1 Clinical | Bayer AG | Blood Coagulation Disorders | Details |
| SKB-336 | SKB-336 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Embolism; Thromboembolism | Details |
| SAL-0104 | SAL-0104; SAL0104 | Phase 1 Clinical | Suzhou Genemen Biotech Co Ltd | Cardiovascular Diseases; Embolism; Ischemic Attack, Transient; Myocardial Infarction; Stroke; Thrombosis; Venous Thromboembolism; Venous Thrombosis | Details |
| STP122G | STP-122G; STP122G | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Embolism and Thrombosis | Details |
| SHR2285 | SHR-2285 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Embolism; Thromboembolism; Thrombosis; Venous Thromboembolism | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Factor XI concentrate (factor XI deficiency), CSL Behring | Approved | Csl Behring Llc | Australia | Factor XI Deficiency | Csl Behring Llc | 2014-07-01 | Factor XI Deficiency | Details | ||
| Human coagulation Factor XI (LFB) | Approved | Lfb Biotechnologies Sas | Hemoleven | EU | Factor XI Deficiency | Lfb Biotechnologies Sas | 1999-07-01 | Factor XI Deficiency | Details |